title: Cataract surgery with primary intraocular lens implantation in children with uveitis: long-term outcomes.
abstract: OBJECTIVE
  To report long-term outcomes of cataract surgery with primary posterior chamber intraocular lens (IOL) implantation in children with chronic uveitis.
  
  
  METHODS
  Department of Ophthalmology, Pitié-Salpêtrière Hospital, Paris, France.
  
  
  METHODS
  Case series.
  
  
  METHODS
  This case series comprised patients younger than 16 years with chronic uveitis who underwent phacoemulsification with primary implantation of a heparin surface-modified poly(methyl methacrylate) posterior chamber IOL in the capsular bag. The intraocular inflammation was fully controlled for at least 3 consecutive months before surgery in all cases. The main outcome measures were final corrected distance visual acuity (CDVA), postoperative inflammation, complications, and level of immunosuppressive treatment.
  
  
  RESULTS
  Twenty-two eyes of 16 children (7 girls, 9 boys; median age at surgery 9.5 years old) were included. Underlying uveitic entities were juvenile idiopathic arthritis in 9 patients; idiopathic uveitis in 4; and Behçet disease, sarcoidosis, and varicella zoster-associated uveitis in 1 patient each. The final CDVA was 0.3 logMAR or better in all cases. Postoperative complications included posterior capsule opacification requiring laser capsulotomy in 2 eyes, glaucoma in 4 eyes, and cystoid macular edema/macular dysfunction in 3 eyes. The mean dose of oral prednisone was 29.5 mg/day preoperatively and 8.13 mg/day at the last follow-up. The median follow-up was 6 years (range 5 to 19 years).
  
  
  CONCLUSIONS
  The results indicate that uveitis is not a formal contraindication to primary IOL implantation in the management of pediatric cataract surgery in cases with full control of intraocular inflammation.
  
  
  BACKGROUND
  No author has a financial or proprietary interest in any material or method mentioned.
authors.affiliation: Department of Ophthalmology, University of Paris VI, Pitié-Salpêtrière Hospital, APHP, Necker Hospital, Paris, France. celineterradaoph@gmail.com
authors.forename: Celine
authors.initials: C
authors.lastname: Terrada
authors.forename: Karina
authors.initials: K
authors.lastname: Julian
authors.forename: Nathalie
authors.initials: N
authors.lastname: Cassoux
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Prieur
authors.forename: Marianne
authors.initials: M
authors.lastname: Debre
authors.forename: Pierre
authors.initials: P
authors.lastname: Quartier
authors.forename: Phuc
authors.initials: P
authors.lastname: LeHoang
authors.forename: Bahram
authors.initials: B
authors.lastname: Bodaghi
mesh_terms: D000293:Adolescent; D058442:Capsule Opacification / Q000209:etiology / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D020099:Coated Materials, Biocompatible; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage; D006493:Heparin; D006801:Humans; D007431:Intraoperative Complications; D053685:Laser Therapy; D053844:Lasers, Solid-State; D019654:Lens Implantation, Intraocular; D007910:Lenses, Intraocular; D008297:Male; D018918:Phacoemulsification; D019904:Polymethyl Methacrylate; D011183:Postoperative Complications; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications* / Q000188:drug therapy
chemical_list: D020099:Coated Materials, Biocompatible; D005938:Glucocorticoids; D006493:Heparin; D019904:Polymethyl Methacrylate